A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Chronic Non-Cancer Pain

被引：0
|
作者：
Webster, Lynn Roy
Yamada, Tadaaki
Ferreira, Juan Camilo Arjona
Davidson, Jennifer
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
901e
引用
收藏
页码：S1194 / S1194
页数：1
相关论文
共 50 条
  • [21] A Randomized, Placebo-Controlled Trial of Lubiprostone for Opioid-Induced Constipation in Chronic Noncancer Pain
    Jamal, M. Mazen
    Adams, Atoya B.
    Jansen, Jan-Peter
    Webster, Lynn R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (05): : 725 - 732
  • [22] Tegaserod for the treatment of chronic constipation:: A randomized, double-blind, placebo-controlled multinational study
    Kamm, MA
    Müller-Lissner, S
    Talley, NJ
    Tack, J
    Boeckxstaens, G
    Minushkin, ON
    Kalinin, A
    Dzieniszewski, J
    Haeck, P
    Fordham, F
    Hugot-Cournez, S
    Nault, B
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (02): : 362 - 372
  • [23] A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy
    Webster, Lynn R.
    Hale, Martin E.
    Yamada, Tadaaki
    Wild, James E.
    JOURNAL OF PAIN RESEARCH, 2020, 13 : 605 - 612
  • [24] Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies
    Camilleri, Michael
    Hale, Martin
    Morlion, Bart
    Tack, Jan
    Webster, Lynn
    Wild, James
    JOURNAL OF PAIN RESEARCH, 2021, 14 : 2179 - 2189
  • [25] A double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in chronic constipation patients
    Ke, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 : 179 - 179
  • [26] Efficacy and tolerability of naldemedine in patient with cancer and opioid-induced constipation: A pooled subgroup analysis of 2 randomized placebo-controlled studies
    Satomi, E.
    Ishiki, H.
    Yokota, T.
    Tada, Y.
    Sato, H.
    Okamoto, M.
    Osaka, I.
    ANNALS OF ONCOLOGY, 2018, 29
  • [27] Preventive effect of naldemedine for opioid-induced constipation in patients with cancer starting opioids: A multicenter, double-blinded, randomized, placebo-controlled, phase 3 trial.
    Hamano, Jun
    Higashibata, Takahiro
    Kessoku, Takaomi
    Kajiura, Shinya
    Hirakawa, Mami
    Ariyoshi, Keisuke
    Oyamada, Shunsuke
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA12014 - LBA12014
  • [28] Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
    Wild, James
    Webster, Lynn
    Yamada, Tadaaki
    Hale, Martin
    DRUGS & AGING, 2020, 37 (04) : 271 - 279
  • [29] Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age
    James Wild
    Lynn Webster
    Tadaaki Yamada
    Martin Hale
    Drugs & Aging, 2020, 37 : 271 - 279
  • [30] Phase 3 study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation (OIC) in cancer patients.
    Harada, Toshiyuki
    Katakami, Nobuyuki
    Murata, Toru
    Shinozaki, Katsunori
    Tsutsumi, Masakazu
    Yokota, Takaaki
    Arai, Masatsugu
    Suzuki, Yura
    Narabayashi, Masaru
    Boku, Narikazu
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345